GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that collaborative
research on the effects of its clinical drug candidate GMI-1271 on
E-selectin, and acetaminophen- induced liver damage was accepted for an
oral presentation at “Digestive
Disease Week,” the annual meeting of the American
Gastroenterological Association, American Association for the Study of
Liver Diseases, American Society for Gastrointestinal Endoscopy and the
Society for Surgery of the Alimentary Tract. The meeting will take place
May 21-24 in San Diego.
The oral presentation, entitled “Alleviation of acute drug-induced liver
injury following acetaminophen overdose by therapeutic blockade of E-
selectin in preclinical mouse model,” is scheduled for 2:15 p.m. PT on
Sunday, May 22. More information on the abstract and meeting is
available here.
“The results in this preclinical model of liver toxicity demonstrate
both the biological activity of GMI-1271 and the possible broader uses
of an E-selectin antagonist. While GlycoMimetics is currently focused on
developing GMI-1271 for treatment of acute myeloid leukemia (AML), this
drug candidate has shown activity in pre-clinical models of multiple
different diseases where E-selectin plays a functional role,” said John
L. Magnani, Ph.D. and Chief Scientific Officer of GlycoMimetics.
About GMI-1271
GMI-1271 is designed to block E-selectin (an adhesion molecule on
vascular endothelial cells.) For its lead clinical indication, GMI-1271
is designed to prevent E-selectin from binding with acute myeloid
leukemia (AML) cells in ways that help the cancer cells evade the
effects of chemotherapy treatment. Preclinical research points to the
drug’s potential role in moving cancerous cells out of the protective
environment of the bone marrow where they hide and escape the effects of
chemotherapy. By blocking E-selectin, GMI-1271 also may protect normal
blood-producing cells, and reduce the toxic side effects of chemotherapy
such as low white blood cell counts that make some patients more prone
to infections. GMI-1271 may also reduce mucositis (inflammation or
lesions in the intestinal tract and mouth), which can be a side effect
of chemotherapy. GlycoMimetics has announced encouraging initial top
line data from the first two cohorts in its ongoing Phase 1/2 clinical
study.
About GlycoMimetics, Inc.
GlycoMimetics is a Phase 3 clinical-stage biotechnology company
developing its proprietary drug candidate, rivipansel, a pan-selectin
antagonist, for the treatment of vaso-occlusive crisis in sickle cell
disease, through its strategic partner, Pfizer. GlycoMimetics’s
wholly-owned lead drug candidate, GMI-1271, an E-selectin antagonist, is
being evaluated for AML and other blood disorders, for which
differentiating initial data from an ongoing Phase 1/2 study have been
announced. A third candidate, GMI-1359, a combined CXCR4 and E-selectin
antagonist, is being readied for the clinic in 2016. Fueling the
pipeline, an in-house discovery and research group is focused on novel
glycomimetic drugs to address unmet medical needs resulting from
diseases in which carbohydrate biology plays a key role. GlycoMimetics
is located in Rockville, MD in the BioHealth Capital Region. Learn more
at www.glycomimetics.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160425006459/en/
Copyright Business Wire 2016